Signs of dehydration worth acting on

Picking up post #12: that is the part I would want checked first.

Allergic reactions: true allergy (anaphylaxis, severe rash) is rare with these peptide compounds but possible. Distinguishing true allergy from GI intolerance matters.

Psychological adverse events: mood changes, anxiety, or suicidal ideation warrant discussion with a mental health professional. These are rare but real.

Reporting to regulatory agencies: if you have had a serious event, reporting it to the regulatory agency in your country can help with signal detection across the population.

Serious and unexpected events are the ones to document and report. Serious means hospitalization-level serious. Unexpected means not in the drug's known profile. Both together warrant official reporting.

How to document: date, exact symptom or event, severity, duration, outcome, any medical attention sought. Detailed documentation is far more useful than a vague report.

I read post #18 twice before replying, because I had assumed the opposite.

Where to report: in many countries there is a pharmacovigilance system where adverse events can be reported. FDA MedWatch in the US, Yellow Card in UK, EudraVigilance in EU.

I read post #19 twice before replying, because I had assumed the opposite.

Pancreatitis is a genuine serious adverse event to know: severe epigastric pain, back pain, elevated lipase (≥3× upper limit of normal). If this constellation appears, stopping the drug and seeking urgent evaluation is appropriate.

This follows post #19 rather than contradicting it.

Acute kidney injury: rare but reported. Symptoms (decreased urine output, creatinine elevation) warrant urgent evaluation. Severe dehydration during weight loss is a risk factor.

Medullary thyroid carcinoma is the reason these compounds are contraindicated in people with personal or family history of MTC or multiple endocrine neoplasia type 2. Rodent toxicology showed a signal; human evidence of causation is absent but caution is appropriate.

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.

Where to report: in many countries there is a pharmacovigilance system where adverse events can be reported. FDA MedWatch in the US, Yellow Card in UK, EudraVigilance in EU.

Picking up post #23: that is the part I would want checked first.

How to document: date, exact symptom or event, severity, duration, outcome, any medical attention sought. Detailed documentation is far more useful than a vague report.

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

Pancreatitis is a genuine serious adverse event to know: severe epigastric pain, back pain, elevated lipase (≥3× upper limit of normal). If this constellation appears, stopping the drug and seeking urgent evaluation is appropriate.

Psychological adverse events: mood changes, anxiety, or suicidal ideation warrant discussion with a mental health professional. These are rare but real.

For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.